After gaining high-profile backing from Sanofi last November, French venture firm Jeito Capital has pulled together more partners to close its first fund at 534 million euros ($630 million).
That large pool of capital will go toward financing between 12 and 15 European biopharmas and contributes to the mission of CEO and founder Rafaèle Tordjman, M.D., Ph.D., who was tasked by the French government with boosting the biotech ecosystem in the country earlier this summer. Jeito will invest up to $100 million in a portfolio company.